Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells

Cancer Science

Volumn 105, Issue 6, 2014, Pages 683-689

  Serizawa, Masakuni ^a   Murakami, Haruyasu ^a   Watanabe, Masaru ^a,b   Takahashi, Toshiaki ^a   Yamamoto, Nobuyuki ^a,b   Koh, Yasuhiro ^a,b  

^a SHIZUOKA CANCER CENTER   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Efatutazone; Epidermal growth factor receptor tyrosine kinase inhibitor resistance; Motility; Non small cell lung cancer; Peroxisome proliferator activated receptor gamma

Indexed keywords

CRK LIKE PROTEIN; EFATUTAZONE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA2;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUCIFERASE ASSAY; LUNG CANCER CELL LINE; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WOUND CLOSURE;

EFATUTAZONE; EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR RESISTANCE; MOTILITY; NON-SMALL CELL LUNG CANCER; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PPAR GAMMA; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMAD2 PROTEIN; THIAZOLIDINEDIONES; TRANSFORMING GROWTH FACTOR BETA2; WOUND HEALING;

EID: 84901801670     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12411     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Yang P, Allen MS, Aubry MC et al. Clinical features of 5, 628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005; 128: 452-62.
3. Koyi H, Hillerdal G, Branden E. A prospective study of a total material of lung cancer from a county in Sweden 1997-1999: gender, symptoms, type, stage, and smoking habits. Lung Cancer 2002; 36: 9-14.
4. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-8.
5. Lindeman NI, Cagle PT, Beasley MB et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013; 8: 823-59.
6. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007; 98: 1817-24.
7. Blanquicett C, Roman J, Hart CM. Thiazolidinediones as anti-cancer agents. Cancer Ther 2008; 6: 25-34.
8. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 2004; 5: 419-29.
9. Nemenoff RA, Weiser-Evans M, Winn RA. Activation and molecular targets of peroxisome proliferator-activated receptor-gamma ligands in lung cancer. PPAR Res 2008; 2008: 156875.
10. Lehrke M, Lazar MA. The many faces of PPARgamma. Cell 2005; 123: 993-9.
11. Shimazaki N, Togashi N, Hanai M et al. Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model. Eur J Cancer 2008; 44: 1734-43.
12. Copland JA, Marlow LA, Kurakata S et al. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene 2006; 25: 2304-17.
13. Pishvaian MJ, Marshall JL, Wagner AJ et al. A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer 2012; 118: 5403-13.
14. Study of erlotinib with or without investigational drug (CS-7017) in subjects with advanced non-small cell lung cancer [NCT01101334]. [Cited 2014.] Available from URL: http://clinicaltrialsgov/ct2/show/NCT01101334.
15. Serizawa M, Takahashi T, Yamamoto N, Koh Y. Combined treatment with erlotinib and a transforming growth factor-beta type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells. J Thorac Oncol 2013a; 8: 259-69.
16. Serizawa M, Takahashi T, Yamamoto N, Koh Y. Genomic aberrations associated with erlotinib resistance in non-small cell lung cancer cells. Anticancer Res 2013b; 33: 5223-33.
17. Lee CH, Kim HD, Shin SM, Kim SG. A novel mechanism of PPARgamma regulation of TGFbeta1: implication in cancer biology. PPAR Res 2008; 2008: 762398.
18. Koizumi F, Shimoyama T, Taguchi F, Saijo N, Nishio K. Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. Int J Cancer 2005; 116: 36-44.
19. Padua D, Massague J. Roles of TGFbeta in metastasis. Cell Res 2009; 19: 89-102.
20. Reka AK, Kurapati H, Narala VR et al. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. Mol Cancer Ther 2010; 9: 3221-32.
21. Cheng HC, Ho TC, Chen SL, Lai HY, Hong KF, Tsao YP. Troglitazone suppresses transforming growth factor beta-mediated fibrogenesis in retinal pigment epithelial cells. Molecular Vis 2008; 14: 95-104.
22. Lee SJ, Yang EK, Kim SG. Peroxisome proliferator-activated receptor-gamma and retinoic acid X receptor alpha represses the TGFbeta1 gene via PTEN-mediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosphorylation. Mol Pharmacol 2006; 70: 415-25.
23. Wei S, Yang J, Lee SL, Kulp SK, Chen CS. PPARgamma-independent antitumor effects of thiazolidinediones. Cancer Lett 2009; 276: 119-24.
24. Han S, Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways.Mol Cancer Ther 2006; 5: 430-7.
25. Li X, Yang X, Xu Y, Jiang X, Nan F, Tang H. Troglitazone inhibits cell proliferation by attenuation of epidermal growth factor receptor signaling independent of peroxisome proliferator-activated receptor gamma. Cell Res 2009; 19: 720-32.
26. Riely GJ, Kris MG, Zhao B et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007; 13: 5150-5.
27. Maruyama R, Wataya H, Seto T, Ichinose Y. Treatment after the failure of gefitinib in patients with advanced or recurrent non-small cell lung cancer. Anticancer Res 2009; 29: 4217-21.
28. Nishie K, Kawaguchi T, Tamiya A et al. Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. J Thorac Oncol 2012; 7: 1722-7.
29. Asami K, Okuma T, Hirashima T et al. Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations.Lung Cancer 2013; 79: 276-82.
30. Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, Riely GJ. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011; 17: 6298-303.